XAIR

Beyond Air, Inc. (XAIR) - Q1 2024 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2024. Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing the LungFit® platform, which generates nitric oxide (NO) from ambient air. The company's primary commercial product, LungFit® PH, received FDA approval in June 2022 for treating persistent pulmonary hypertension of the newborn (PPHN). The company also operates two development segments: Beyond Cancer (80% owned, focusing on ultra-high concentration NO for solid tumors) and a neurological program targeting autism spectrum disorder (ASD).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased to $0.7 million from $0.1 million, driven by the commercial launch of LungFit® PH. However, the company recorded a gross loss of $0.3 million due to supply chain infrastructure costs and depreciation of leased devices.
• Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased significantly to $7.2 million from $10.9 million, primarily due to a $2.2 million reduction in stock-based compensation.
• Operating Loss Improvement: The operating loss narrowed to $13.6 million from $15.9 million year-over-year.
• Other Income: Non-operating income decreased to $0.5 million from $0.8 million, largely due to higher interest expenses ($0.96 million vs. $0.16 million) offset by gains from changes in the fair value of derivative liabilities.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. With an accumulated deficit of $251.9 million and cash burn of $10.2 million in the quarter, the company expects to require additional funding within one year.
• Funding Options: The company has a $32.9 million available capacity under its At-The-Market (ATM) equity offering and a $12.5 million discretionary tranche available under its Loan and Security Agreement with Avenue Capital, subject to approval.
• Debt Obligations: The company has a $17.5 million principal loan outstanding (Tranche 1) with Avenue Capital, maturing June 1, 2027. Principal repayments are scheduled to begin January 1, 2025, contingent on revenue milestones. A $4.5 million settlement payment to Circassia is due in the second fiscal quarter of 2025.
• Operational Updates:
  • Beyond Cancer: Phase 1a clinical trial data showed no dose-limiting toxicities at 25,000 ppm. A Phase 1b combination study with anti-PD1 is expected to begin before the end of 2024.
  • LungFit® PRO: A U.S. clinical trial for viral pneumonia was paused pending future funding.
  • ASD Program: Expected to progress to Phase 1 first-in-human trials by the end of 2025.

Investor Verification Checklist

• Cash Runway: Verify the timeline for raising additional capital given the "substantial doubt" disclosure and $21.4 million cash balance.
• Debt Covenants: Confirm compliance with the $5.0 million unrestricted cash covenant and revenue milestones required to access the remaining $22.5 million in loan tranches.
• Settlement Liability: Monitor the $4.5 million Circassia settlement payment due in Q2 2025 and its impact on liquidity.
• Revenue Trajectory: Assess the commercial adoption rate of LungFit® PH to determine if it can generate sufficient cash flow to offset the $10M+ quarterly operating burn.
• Stock-Based Compensation: Note the significant reduction in stock-based compensation ($3.4M in Q1 2024 vs $6.1M in Q1 2023) and evaluate if this trend is sustainable or if future dilution is likely.